|
|
|
|
| LEADER |
02398nam a2200409 u 4500 |
| 001 |
EB001892023 |
| 003 |
EBX01000000000000001055170 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200301 r ||| eng |
| 100 |
1 |
|
|a Thompson, Wade
|
| 245 |
0 |
0 |
|a Early biologic treatment versus conventional treatment for the management of Crohn's disease
|h Elektronische Ressource
|b a review of comparative clinical effectiveness and cost-effectiveness
|c Wade Thompson, Charlene Argáez
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c February 13, 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (47 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Tumor Necrosis Factor Inhibitors / economics
|
| 653 |
|
|
|a Adrenal Cortex Hormones / economics
|
| 653 |
|
|
|a Early Medical Intervention
|
| 653 |
|
|
|a Tumor Necrosis Factor Inhibitors / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Adrenal Cortex Hormones / therapeutic use
|
| 653 |
|
|
|a Crohn Disease / drug therapy
|
| 653 |
|
|
|a Immunomodulation
|
| 700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: peer-reviewed summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK543466
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Given the theorized benefits of a top-down approach (early use of biologics), there is growing interest in its clinical effectiveness, safety, and cost-effectiveness compared to a conventional treatment approach, both in children and adults. As such, this report sought to summarize the evidence regarding the clinical and cost-effectiveness of early biologic therapy compared to conventional treatment for Crohn's disease in children and adults. This is an upgrade of a previous CADTH rapid response titled "Early Treatment versus Conventional Treatment for the Management of Luminal Crohn's Disease: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness"
|